Drug Approval | December 12, 2025
Bristol Myers Squibb scores FDA priority review for Opdivo in advanced hodgkin lymphoma
The FDA aims to make a decision by April 8, 2026
The FDA aims to make a decision by April 8, 2026
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
Subscribe To Our Newsletter & Stay Updated
